Medicus Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MDCX$1.83-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
Consolidated Statements of Changes in Shareholders' Equity
| Common shares · Shares to be issued · Additionalpaid-in capital · Accumulateddeficit · AccumulatedOtherComprehensiveIncome · Non-ControllingInterest · Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| # | $ | # | $ | $ | $ | $ | $ | $ | |
| Balance as of December 31, 2023 | 8,076,673 | 18,761,250 | - | - | 98,585 | (17,748,387) | - | - | 1,111,448 |
| Issuance of common shares upon conversion of debt | 1,308,798 | 5,210,962 | - | - | - | - | - | - | 5,210,962 |
| Issuance of common shares in connection with a private placement, net of issuance costs of $375,000 | 1,461,250 | 5,470,000 | - | - | - | - | - | - | 5,470,000 |
| Issuance of common shares and warrants in connection with initial public offering, net of issuance costs of $2,218,014 | 970,000 | 1,075,983 | - | - | 708,708 | - | - | - | 1,784,691 |
| Stock-based compensation | - | - | - | - | 713,119 | - | - | - | 713,119 |
| Net loss and comprehensive loss for the year | - | - | - | - | - | (11,155,516) | - | - | (11,155,516 |
| Balance as of December 31, 2024 | 11,816,721 | 30,518,195 | - | - | 1,520,412 | (28,903,903) | - | - | 3,134,704 |
| Issuance of common shares and warrants in connection with Regulation A offering, net of issuance costs of $483,020 | 1,490,000 | 2,076,507 | - | - | 1,612,474 | - | - | - | 3,688,981 |
| Issuance of common shares in connection with SEPA | 3,783,693 | 9,006,270 | - | - | - | - | - | - | 9,006,270 |
| Issuance of common shares and warrants in connection with June equity financing, net of offering costs of $809,606 | 2,260,000 | 3,961,899 | - | - | 2,234,495 | - | - | - | 6,196,394 |
| Issuance of common shares for asset acquisition | 1,397,184 | 2,129,410 | 205,980 | 313,934 | - | - | - | 105,161 | 2,548,505 |
| Share issuance costs | - | (653,504) | - | - | - | - | - | - | (653,504) |
| Issuance of common shares upon exercise of stock warrants | 4,283,705 | 9,874,998 | - | - | - | - | - | - | 9,874,998 |
| Issuance of common shares upon exercise of stock options | 145,000 | 162,400 | - | - | - | - | - | - | 162,400 |
| Stock-based compensation | - | - | - | - | 1,512,194 | - | - | - | 1,512,194 |
| Warrants issued under warrant inducements | - | - | - | - | 11,837,298 | - | - | - | 11,837,298 |
| Deemed dividend on warrant inducements | - | - | - | - | (11,837,298) | - | - | - | (11,837,298) |
| Net loss and comprehensive loss for the year | - | - | - | - | (35,444,215) | - | (146) | (35,444,361) | |
| Other comprehensive income for the year | - | - | - | - | - | - | 10,880 | (150) | 10,730 |
| Balance as of December 31, 2025 | 25,176,303 | 57,076,175 | 205,980 | 313,934 | 6,879,575 | (64,348,118) | 10,880 | 104,865 | 37,311 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.